NCT02840461View on ClinicalTrials.gov

Clinical Endpoint Study of Ivermectin 1% Cream

PHASE3CompletedINTERVENTIONAL
Enrollment

630

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Moderate to Severe Papulopustular Rosacea
Interventions
DRUG

Ivermectin Cream, 1%

DRUG

Placebo/Vehicle cream

Trial Locations (1)

60005

Investigator site 1, Arlington Heights

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT02840461 - Clinical Endpoint Study of Ivermectin 1% Cream | Biotech Hunter | Biotech Hunter